News
Lifesciences
BioPharmaAPAC
May 8, 2025
India to Gain Faster, Affordable Access to CAR T Therapy as NKure Therapeutics Partners with CRISPR Therapeutics
Strategic collaboration to co-develop CTX112™ aims to address India’s growing burden of B-cell lymphomas with an off-the-shelf, CRISPR-engineered cell therapy offering scalable production and reduced treatment delays.
Lifesciences
THE KEN
Apr 21, 2025
How a 14-member biotech spent just $10M on a product global pharma wants to lap up
One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price.
Lifesciences
Ophthamology Times
Apr 14, 2025
Eyestem releases positive results from phase 1 trial in patients with geographic atrophy
Eyecyte-RPE trial involved 9 patients with geographic atrophy, using three ascending dose levels of hiPSC-derived RPE cells. No serious adverse events were reported, and patients showed an average vision improvement of 14.9 letters on ETDRS tests.
No items found.
2022 All rights reserved
